相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Gerwin Huls et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Treatment of relapsed/refractory acute myeloid leukaemia in adults
Armin Rashidi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies
Kathryn T. Maples et al.
LEUKEMIA & LYMPHOMA (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rituximab maintenance therapy of follicular lymphoma in clinical practice
Ulrich Duehrsen et al.
CANCER MEDICINE (2018)
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Tapan M. Kadia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
Brenda M. Sandmaier et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies
Lionel Ades et al.
HAEMATOLOGICA (2017)
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M. H. Qazilbash et al.
LEUKEMIA (2017)
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)
W. Blum et al.
LEUKEMIA (2017)
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies
Lionel Ades et al.
HAEMATOLOGICA (2017)
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Pierre Hirsch et al.
HAEMATOLOGICA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low-to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy
Bin Liang et al.
ONCOTARGETS AND THERAPY (2017)
Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
M. Hunault-Berger et al.
BLOOD CANCER JOURNAL (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Pierre Hirsch et al.
HAEMATOLOGICA (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
R. S. Komrokji et al.
ANNALS OF ONCOLOGY (2016)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
Anthony D. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Harnessing the immune system in acute myeloid leukaemia
Rebecca Austin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
Gail J. Roboz et al.
FUTURE ONCOLOGY (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
Yong Won Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia
Gaku Oshikawa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents
Dario Ferrero et al.
ANNALS OF HEMATOLOGY (2014)
Immune-Modulating Drugs and Hypomethylating Agents to Prevent or Treat Relapse after Allogeneic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Post-remission therapy for acute myeloid leukemia
Richard F. Schlenk
HAEMATOLOGICA (2014)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Daniel A. Pollyea et al.
HAEMATOLOGICA (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
G. Ramsingh et al.
LEUKEMIA (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interferon may be back on track to treat acute myeloid leukemia
Evelien L. J. M. Smits et al.
ONCOIMMUNOLOGY (2013)
Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups
Marysia Hengeveld et al.
ANNALS OF HEMATOLOGY (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
Amel Sebaa et al.
GENES CHROMOSOMES & CANCER (2012)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Katja Sockel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
D. A. Pollyea et al.
LEUKEMIA (2012)
A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
Y. Boumber et al.
LEUKEMIA (2012)
Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
Amy E. DeZern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
Evelien Kneppers et al.
BLOOD (2011)
Interferon-α in acute myeloid leukemia: an old drug revisited
S. Anguille et al.
LEUKEMIA (2011)
Cytarabine Dose for Acute Myeloid Leukemia
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
Bob Lowenberg et al.
BLOOD (2010)
Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia
I. P. Palva et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Low-Dose Azacitidine After Allogeneic Stem Cell Transplantation for Acute Leukemia
Elias Jabbour et al.
CANCER (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells
C Lehmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
AH Goldstone et al.
BLOOD (2001)
分享论文
